Navigation Links
Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
Date:1/7/2008

SAN DIEGO, Jan. 7 /PRNewswire/ -- Trius Therapeutics, Inc. announced today that it initiated its first Phase 1 clinical trial of TR-701, an antibacterial drug candidate intended for treatment of patients with serious Gram-positive bacterial infections, including those caused by MRSA and other drug-resistant strains. The eighty-eight subject single and multiple ascending dose trial will test tolerability, safety and pharmacokinetics of the oral dosage form of the drug and will compare its properties to those of Zyvox(R), the only marketed drug in the oxazolidinone class.

"In this early clinical trial our goal is to demonstrate the potential of TR-701 to provide patients and clinicians with more convenient dosing and a broader safety margin than the current standard of care," stated Jeffrey Stein,

Ph.D., President and CEO of Trius Therapeutics. "TR-701's potential for once-daily dosing, supported by results of prior exploratory human testing in Korea and preclinical animal data, is expected to translate into an increased therapeutic index and thereby provide an important option for the treatment of serious infections caused by drug-resistant bacterial pathogens."

"Because the majority of bacterial infections in the hospital are now caused by bacteria resistant to many antibiotics, and such infections are also spreading alarmingly within the community, there is an ever growing need for potent yet safe orally available drugs to treat infections caused by resistant Gram-positive pathogens," stated Philippe Prokocimer, M.D., Chief Medical Officer of Trius. "We believe that TR-701 has the potential to become a first-line, best-in-class, treatment for infections caused by these pathogens."

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by resistant pathogens. The company's lead product candidate, TR-701 is a novel oral and IV oxazolidino
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
2. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
3. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
4. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
5. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
6. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
7. Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
8. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
9. Senesco Technologies Initiates Preclinical Studies for Cancer Target
10. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
11. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2008)...pment Plan Completed Successfully, DUBLIN, Irelan...ation,plc (NASDAQ: AMRN ) today announced that th...Food and Drug Administration (FDA) to discuss the,...t of,hypertriglyceridemia. Following these discuss...R101 in hypertriglyceridemia., Dr. Declan Doogan,...
(Date:7/22/2008)...and Apidra(R) Resulted in Significant, Reductions ...the Algorithm Use...ults from the "Adjust to,Target in Type 2 Diabetes...,Counting for Adjustment of Mealtime Insulin Gluli...es Association,s (ADA) medical journal,Diabetes C...
(Date:7/22/2008)...herapy and pegylated enzyme produces significan...ne - - Pegylated enzyme well tole.../ -- Halozyme Therapeutics,Inc. (Nasdaq: HALO ),...cializing products targeting the extracellular mat...pre-clinical animal efficacy data,for its pegylate...
(Date:7/22/2008)...2 /- NicOx S.A.,(Euronext P...pleted the,enrollment of 417 osteoarthritis (OA) p...al pharmacology studies in the United States, in l...als are designed to assess the,blood pressure prof...,naproxen, using the Ambulatory Blood Pressure Mon...
Breaking Medicine Technology:Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 2Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 3Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 5NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 2NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 3Mayo Researchers Say ECG Standards Should Be Revised for Elderly 14432 1Mayo Researchers Say ECG Standards Should Be Revised for Elderly 14432 2CryoCor Announces Web cast and Conference Call of 2007 Year End Results 14427 1CryoCor Announces Web cast and Conference Call of 2007 Year End Results 14427 2Obesity Linked to Poor Prognosis for Some Breast Cancer Patients 14425 1Obesity Linked to Poor Prognosis for Some Breast Cancer Patients 14425 2Obesity Linked to Poor Prognosis for Some Breast Cancer Patients 14425 3Free Egg Donor Contest Ending March 31 14421 1Free Egg Donor Contest Ending March 31 14421 2
(Date:7/25/2008)... Whether you are an Olympian, Professional ...re Five Things You Need to Know about Hydration to... and Sports Center , Mari...a,s premier athletes are heading to Beijing follow...crifice in the hopes of capturing an Olympic medal...
(Date:7/25/2008)... This donation will be used to facilitate t...es for children , Hauppau...ci.com ), a leading integrator of enterprise coll...o conferencing, telepresence, audio visual integra... today that it has donated video conferencing equi...
(Date:7/24/2008)..., N.C. Researchers at Wake Forest University Bap... clinical belief that the hepatitis C virus slows ...tself after HIV patients are treated with a combin...itis C (HCV) infection is more serious in HIV-infe...ing to the Centers for Disease Control. Intravenou...
(Date:7/24/2008)...ly 24 /PRNewswire-USNewswire/ -- Speaker Nancy Pel...in support of the Tom Lantos,and Henry J. Hyde Glo...,Malaria Reauthorization Act of 2008. The bill, wh...this evening by a vote of 303 to 115 and will now ...day the House took an historic vote to pass landma...
Breaking Medicine News(10 mins):Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 2Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 3Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 4Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 5Health News:Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 2Health News:Researchers disprove long-standing belief about HIV treatment 2Health News:Researchers disprove long-standing belief about HIV treatment 3Health News:Pelosi Statement on House Passage of Global AIDS Legislation 2
...treating tissue at the back of the mouth is succes...en and 30 per cent of women have a problem with sn...em is vibrations in the soft palate - the area of ...la, the sides of the tonsils, and the base of the ...
...ften have gastrointestinal symptoms such as incont...frequent stomach and intestinal troubles may be a ...a side effect of diabetes medications, researchers...tburn, bloating, nausea, vomiting, diarrhea and co...
...tember 11 terrorist acts in New York and Washingto...put on hold for several days, which severely affec...ceuticals. Most radiopharmaceuticals are shipped v...hese products are either radioactive themselves or...
... Administration has approved the first hormone-rel...ganon, Inc., effectively blocks conception between...that for every 100 women who use it for a year, on... That rate is similar to both the birth control pi...
Other Medicine News:
... OPMI Vario/NC33 System, Carl Zeiss has successful...et. , ,The success of this instrument is by n...ct and stylish design. Maximum ergonomic convenien...n to be used with a surgical microscope, allowing ...
...g; Suction Punch Forceps provide superior tissue e.... Shutt® Suction Graspers offer an aggressive ...he jaws. Both feature a unique stress pin bufferin...In use, the stress pin buffering system applies in...
Leg holder for arthroscopy.
Osteoprep instruments provide an array of bone shaping devices especially suited for notchplasties.
Medicine Products: